$p16^{\text{INK4a}}$ hypermethylation and $p53$, $p16$ and $MDM2$ protein expression in Esophageal Squamous Cell Carcinoma

Noushin Taghavi1,2, Firouzeh Biramijamal1, Masoud Sotoudeh2, Hooman Khademi2, Reza Malekzadeh2, Omeed Moaven3, Bahram Memar4, Azadeh A'rabi3 and Mohammad Reza Abbaszadegan*3

Abstract

Background: Tumor suppressor genes $p53$ and $p16^{\text{INK4a}}$ and the proto-oncogene $MDM2$ are considered to be essential G1 cell cycle regulatory genes whose loss of function is associated with ESCC carcinogenesis. We assessed the aberrant methylation of the $p16$ gene and its impact on $p16^{\text{INK4a}}$ protein expression and correlations with $p53$ and $MDM2$ protein expressions in patients with ESCC in the Golestan province of northeastern Iran in which ESCC has the highest incidence of cancer, well above the world average.

Methods: Cancerous tissues and the adjacent normal tissue obtained from 50 ESCC patients were assessed with Methylation-Specific-PCR to examine the methylation status of $p16$. The expression of $p16$, $p53$ and $MDM2$ proteins was detected by immunohistochemical staining.

Results: Abnormal expression of $p16$ and $p53$, but not $MDM2$, was significantly higher in the tumoral tissue. $p53$ was concomitantly accumulated in ESCC tumor along with $MDM2$ overexpression and $p16$ negative expression. Aberrant methylation of the $p16^{\text{INK4a}}$ gene was detected in 31/50 (62%) of esophageal tumor samples, while two of the adjacent normal mucosa were methylated ($P < 0.001$). $p16^{\text{INK4a}}$ aberrant methylation was significantly associated with decreased $p16$ protein expression ($P = 0.033$), as well as the overexpression of $p53$ ($P = 0.020$).

Conclusions: $p16$ hypermethylation is the principal mechanism of $p16$ protein underexpression and plays an important role in ESCC development. It is associated with $p53$ protein overexpression and may influence the accumulation of abnormally expressed proteins in $p53$-$MDM2$ and $p16$-$Rb$ pathways, suggesting a possible cross-talk of the involved pathways in ESCC development.

Background

Esophageal cancer is the fifth leading cause of cancer-related deaths in Iran [1]. It is also considered the second most common type of cancer in both males and females in Golestan province of northeastern Iran (Age Standardized Rate: 22.57 in males and 19.89 in females in 10^5 persons/year) (unpublished data). This region is located in the “Esophageal Cancer Belt,” stretching from China westward through central Asia to northern Iran, where there is a high incidence of Esophageal Squamous Cell Carcinoma (ESCC)[2,3]. Although several environmental risk factors are proposed for ESCC, the specific underlying genetic alterations have not been well defined for this region to date [3,4].

Several genetic and epigenetic alterations are involved in esophageal carcinogenesis [5-7]. Investigation of alterations in oncogenes and tumor suppressor genes implicated in esophageal tumorigenesis may provide molecular markers for early diagnosis and therapeutic intervention[8].

Tumor suppressor genes $P53$ and $p16^{\text{INK4a}}$ and the proto-oncogene $MDM2$ (Murine Double Minute 2), are considered to be essential G1 cell cycle regulatory genes and whose loss of function is associated with cancer development [9].

* Correspondence: abbaszadeganm@mums.ac.ir
3 Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran
Full list of author information is available at the end of the article
In response to DNA damage, p53 protein induces G1 cell cycle arrest or apoptosis [10]. Abnormalities of this gene, such as gene mutation, can lead to the loss of regulation of cell growth, DNA repair, or apoptosis, all of which are responsible for carcinogenesis [11]. The product of the MDM2 gene, which is induced by p53, appears to play a critical role in regulating the level of the wild-type p53 protein. It can bind to and inactivate the transcriptional activity of p53, resulting in the abrogation of p53 anti-proliferative and apoptotic effects, and consequently the deregulation of cell overgrowth, which leads to tumor development [11-13]. Acting as a cyclin-dependent kinase inhibitor (CDKI), p16\textsuperscript{INK4a} binds to and inhibits the activity of CDK4 and CDK6 and arrests the cell cycle in the G1/S phase in a p53-dependent pathway [14,15].

DNA methylation in the normally unmethylated promoter region of tumor suppressor genes, such as p16\textsuperscript{INK4a}, is a critical mechanism for their inactivation and is commonly associated with the repression of gene transcription which promotes the development of cancers, including ESCC carcinogenesis [16-18]. Previous reports from Iran showed that p16 hypermethylation in the promoter region is a common mechanism for the inactivation of this gene in ESCC and gastric cancer development in Khorasan province of northeastern Iran [19,20]. Aberrant p16 hypermethylation is also suggested as a possible epigenetic risk factor in familial ESCC [21].

In addition, p53 alterations, including the mutation of p53, have been identified as a frequent event in ESCC development in northeastern Iran [22,23].

In the present study, we examined the methylation status of the p16 gene, in 50 ESCC patients using Methylation Specific PCR (MSP) assay. p16, p53 and MDM2 protein expression was assessed to identify the association of p16\textsuperscript{INK4a} gene methylation with the expression of these cell cycle proteins in a population with a high incidence of ESCC in northeastern Iran.

**Methods**

**Study population and sample collection**

A total of 50 ESCC patients (ages ranging from 35-83 years) were recruited from May 2006 to June 2007, from among patients referred to the two main referral oncology centers in northeastern Iran: Atrak clinic, a referral center for upper GI cancers in Golestan province, and Omid Oncology Hospital, referral oncology hospital in northeastern Iran. It is estimated that approximately 95% of upper GI cancer patients in this region are referred to Atrak clinic [24]. Patients did not receive any adjuvant therapy (radiotherapy or chemotherapy) or blood transfusions. Follow up carried out 6 to 24 months afterwards. Demographic characteristics and information about social habits, including the smoking or consumption of cigarettes, the hookah and nass (a mixture of tobacco, ash, and lime) [4], were obtained by trained interviewers using a standard questionnaire. All patients underwent upper GI endoscopy. Tissue samples of esophageal tumor and macroscopically adjacent normal tissue from a site, remote from the tumor, were dissected and fixed in 70% alcohol and embedded in paraffin. The presence of normal and tumor tissue was assessed by histological evaluation. The Research Ethics Committees of Tehran University of Medical Sciences and Mashhad University of Medical Sciences approved the study design. All eligible patients signed a written informed consent prior to participating in the study.

**DNA Extraction**

Areas of the tumor in which tumor cells represented >70% of all cells were extracted. Genomic DNA was extracted from paraffin-embedded tissues by use of xylene and alcohol. After digestion by proteinase K, DNA was extracted and purified by the phenol/chloroform/isoamyl alcohol method and precipitated in ethanol, as previously described [20].

**Bisulfite modification**

Bisulfite modification of DNA results in conversion of unmethylated cytosine residues into uracil, whereas, the methylated cytosine residues, remains unchanged.

Briefly, 2 μg of DNA was denatured in 3 mol/L NaOH (2 μL) for 10 min at 50°C and then modified by adding a 500 μl of a freshly prepared bisulfite solution (2.5 M sodium bisulfate and 125 mM hydroquinone) following to an incubation for 12 h at 50°C. DNA samples were desalted through a column (Wizard DNA Clean-Up System, Promega), and then treated with 3 mol/L NaOH (5 μL) for 10 min at 37°C, followed by precipitation with 75 μl ammonium acetate (5 M). The pellet was washed with 2.5 volumes of ethanol, dried, and re-suspended in 20 μl tris (pH 8.0, 5 mM), then stored at -70°C until used for MSP.

**Methylation-Specific PCR (MSP)**

After bisulfite treatment, DNA samples were assayed by methylation-specific PCR. The PCR mixture was prepared in a 25 μL volume containing 1× buffer (Finzymes, Finland) with 2 mmol/L of MgCl\textsubscript{2}, 500 nmol/L of each primer (previously described sequences[20]), 0.2 mmol/L of dNTPs, 1 U of Hot Start Taq polymerase (Finzymes, Finland), and bisulfite-modified DNA. DNA amplification was performed in a thermocycler (Perkin-Elmer Corp.). The PCR amplification consisted of an initial hot-start step at 95°C for 10 min, followed by 40 cycles (45 s at 95°C, 45 s at 60°C, 60 s at 72°C), and a final 10 min extension at 72°C. Each MSP was repeated at least twice. In addition to a negative control, DNA from L132 and...
H1299 cells were used as a positive control for unmethylated and methylated alleles, respectively. PCR products were loaded on 2.5% agarose gel and 6% poly-acrylamide gel, stained with silver nitrate dyes and visualized under UV illumination.

**Immunohistochemistry**

Paraffin embedded sections (3 μm thick) of esophageal tumor and adjacent normal tissue were used to perform IHC reaction. Briefly, the sections were mounted on poly-L-lysine-coated slides and dried at 60°C for 1 hour. The sections were dewaxed and rehydrated in a xylene-ethanol series and boiled in the Target Retrieval Solution of Dako (Dako, Carpinteria, CA, USA) in a microwave oven for 45 min at 37°C with a 1:50 dilution; and, for MDM2, IgM mouse monoclonal clone 1B10 (carboxy terminus of MDM2) was used (Novocastra Laboratories, New Castle, UK) with a 1:100 dilution, incubated overnight. After two washes in PBS, sections were incubated with EnVisionTM+System/HRP, Rabbit/Mouse (DAB+) (DakoCytomation, Carpinteria, CA, USA), a secondary antibody. The immunoreactivity was detected using diaminobenzidine (DAB) (DakoCytomation, Carpinteria, CA, USA) as a chromogen. Finally, sections were counterstained with Meyer’s Hematoxylin, dehydrated through a sequence of increasing concentrations of alcoholic solutions and cleared in xylene. During each IHC assay, proof sections and cleared in xylene. During each IHC assay, proof sections were incubated with negative control slides on which the primary antibody was omitted. 

**Statistical analysis**

The Statistical Package for the Social Sciences software version 16.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. The correlation between two variables was evaluated using Pearson’s chi-square and Fisher’s exact tests. Survival rates were calculated by the Kaplan-Meier method. Using the log-rank test, we compared the survival of ESCC patients according to various clinicopathological factors. A 2-sided P value < 0.05 was considered as the significant statistical level.

**Results**

Fifty ESCC patients (ages ranging from 35 to 83 years; with the mean age of 59.02 ± 11.41 years) were enrolled in this study. Twenty five (50%) patients were men and 25 were women with the male to female ratio of 1. Tumor sizes ranged from 2 to 12 cm, with a mean diameter was 4.97 ± 2.13 cm. Clinicopathological characteristics of the ESCC patients are summarized in table 1.

The methylation status of 5’ CpG island of the p16 gene was detected in 31/50 (62%) esophageal tumor samples, while two of the adjacent normal mucosa were methylated (P < 0.001). No significant association was found between the methylation status of the p16 gene and the factors studied, including age, sex, tumor histopathology, tumor site and size, and opium and tobacco use (cigarette and hookah smoking, Nass chewing) (Table 1). Figure 1 represents MSP analysis of p16 gene.

**Immunohistochemical staining**

IHC staining of p16, p53 and MDM2 are represented in figure 2.

a) **Immunohistochemical staining of p16, p53 and MDM2**

The negative expression of the p16 protein was detected in 28/50 (56%) tumors and only 7/50 (14%) normal tissues (P < 0.001).

The positive expression of p53 and MDM2 proteins in the nuclei was detected in 31/50 (62%) and 21/50 (42%) tumor tissues and in 7/50 (14%) and 30/50 (60%) normal esophageal tissues, respectively. There was a significant difference between tumor and normal tissues for p53 staining (P = 0.001), but not for MDM2. The histological grade of differentiation was not associated with the IHC staining of p16, p53 and MDM2.

b) **Concomitant p16, p53 and MDM2 protein expression in ESCC**

The overexpression of MDM2 was not significantly associated with the abnormal expression of p53. There was neither significant correlation between p16 and p53, nor between p16 and MDM2 immunoreactivity in esophageal tumor and normal samples, independently. Concomitant abnormal accumulation of the p53 protein with either MDM2 overexpression or abnormal underexpression of p16 was significantly more frequent in tumoral tissue compared to normal tissue: p16+/p53+/MDM2 was detected in 20/50 (40%) tumors and in none of the normal tissues; whereas the opposite combination (p16+/p53-) was found in 11/50 (22%) tumors and 36/50 (72%) normal specimens, with a statistically significant difference between tumor and normal samples in these subgroups (P < 0.001). In tumoral and normal tissues, the proportion of p53+/MDM2+ was 16/50 (32%) and 2/50 (4%), while p53-/MDM2- was detected in 14/50 (28%) and 14/50 (28%) respectively, with a statistically significant difference (P < 0.001). On the other hand, with MDM2+/p16-, there was not a significant difference in tumors compared to normal tissues (P = 0.078).

We also investigated the association between the p16/p53/MDM2 profile and tobacco use, histology of tumor,
and p16 methylation status in ESCC. The samples were divided into four groups according to the number of alterations detected. The p16-/p53+/MDM2+ immunoprofile was only observed in the tumor tissues and not in the normal adjacent tissue (P < 0.001). Similarly we observed this profile more frequently in p16-methylated tumors (P = 0.035). We did not find any significant association between tobacco consumption and different histological subtypes with the different immunoprofiles. (Table 2)

Correlation between p16, p53 and MDM2 immunoreactivity, and hypermethylation of p16
Twenty one out of thirty one (67.7%) methylation-positive esophageal tumors showed a complete lack of immunoreactivity of p16. Twelve out of nineteen (63.2%) of unmethylated tumors represented diffuse immunoreactivity, whereas 7/19 (36.8%) of unmethylated tumors were not immunostained for p16. p16 negative staining was significantly correlated with p16 methylation (P = 0.033). Significant association was observed between abnormal accumulation of p53 and p16 hypermethylation (p = 0.020). Moreover, p16 methylation was more frequent in cases with concomitant accumulation of p53 and loss of p16 proteins i.e. 17/20 (85%), compared to the cases with p16 expressed and p53 negative, 4/11 (36.36%) (P = 0.01). p16 methylation was not associated with MDM2 overexpression. (Table 1)

Patients’ Survival
The 6-months, 1- year, and 2-year survival rates were 78%, 43%, and 28% in tumors with p16 hypermethylation and 43%, 14%, and 0% in tumors without p16 hypermethylation, respectively. The median survival duration of patients with p16 hypermethylation was 8 months, whereas it was 5 months for patients without hypermeth-

| Table 1: Distribution of p16 methylation status according to clinicopathological features and protein expressions in ESCC tumors |
| --- |
| **Number (%)** | methylated | unmethylated | p value |
| **Age** | | | | |
| <60 | 25 (54.3) | 16 (59.3) | 9 (47.4) | 0.421 |
| ≥60 | 21 (45.7) | 11 (40.7) | 10 (52.6) | |
| **Gender** | | | | |
| Male | 25 (50) | 15 (48.4) | 10 (52.6) | 0.773 |
| Female | 25 (50) | 16 (51.6) | 9 (47.4) | |
| **Histology** | | | | |
| Well | 25 (55.6) | 15 (33.3) | 10 (22.2) | 0.211 |
| Moderate | 13 (28.9) | 9 (20.0) | 4 (8.8) | |
| Poor | 7 (15.6) | 2 (4.4) | 5 (11.1) | |
| **Tumor site** | | | | |
| Upper | 1 (2.8) | 0 (0.0) | 1 (5.9) | 0.854 |
| Middle | 23 (63.9) | 12 (63.2) | 11 (64.7) | |
| Lower | 12 (33.3) | 7 (36.8) | 5 (29.4) | |
| **Tobacco use** | | | | |
| Positive | 14 (30.4) | 8 (29.6) | 6 (31.6) | 0.896 |
| Negative | 32 (69.6) | 19 (70.4) | 13 (68.4) | |
| **p16 protein** | | | | |
| Positive | 22 (44) | 10 (32.3) | 12 (63.2) | 0.033 |
| Negative | 28 (56) | 21 (67.7) | 7 (36.8) | |
| **p53 protein** | | | | |
| Positive | 31 (62) | 23 (74.2) | 8 (42.1) | 0.020 |
| Negative | 19 (38) | 8 (25.8) | 11 (57.9) | |
| **MDM2 protein** | | | | |
| Positive | 21 (42) | 16 (51.6) | 5 (26.3) | 0.080 |
| Negative | 29 (58) | 15 (48.4) | 14 (73.7) | |
ylation. The 6 months, 1-year, and 2-year survival rates were 67%, 33%, and 33% in cases with \( p16 \) expression group and 62%, 31% and 18% in the cases with loss of \( p16 \), respectively. The median survival duration of patients with and without loss of \( p16 \) expression was 8 and 10 months, respectively.

There was no statistically significant difference in survival rates based on the \( p16 \) hypermethylation status or \( p16 \) protein expression.

**Discussion**

Golestan province in northeastern Iran has a high incidence of ESCC, which is well above the world average. To better understand some aspects of the complex genetic/epigenetic alterations in this high incidence region, we investigated the role of some components of \( p53 \)-MDM2 and \( p16-Rb \) pathways of cell cycle regulation and their possible cross-talk in ESCC tumorigenesis. Thus, we assessed \( p16 \) hypermethylation as an important mechanism of gene silencing, its impact on the \( p16 \) protein expression, along with its correlation with the \( p53 \) and MDM2 protein expression.

We showed that \( p16 \) protein expression was significantly associated with methylation of the \( p16 \) gene, indicating that \( p16 \) methylation may play a critical role in the silencing of this important tumor suppressor gene. On the other hand, significant differences in both methylation and loss of protein expression of \( p16 \) in tumoral tissue compared to the normal tissue confirms the critical role of these genetic and epigenetic alterations in the development of ESCC in this high-incidence region. In this study, \( p16 \) hypermethylation was observed in 62% of the patients. Previous reports of \( p16 \) methylation varied between 40-90% among ESCC patients in the Far East. Xing et al [27] studied 40 ESCC patients and detected the \( p16 \) gene hypermethylation in 40% of tumor samples. Whereas, Hardie et al [28] and Hibi et al [29] reported promoter methylation of the \( p16 \) gene in 85% (18/21) and 82% (31/38) of esophageal carcinoma, respectively. Wang...
et al [30] showed the aberrant hypermethylation of \(p16\), as a frequent event, in 88% of ESCC patients in China. Abbaszadegan et al reported 73.3% \(p16\) gene methylation in ESCC samples in Khorasan, another province in the northeastern Iran. In support of their data, this study indicates the critical role of \(p16\) methylation in ESCC development in this high risk region [19].

In this study, we also examined \(p16\) methylation in normal tissue adjacent to tumor, in order to clarify whether \(p16\) methylation may have been occurred in the background of tumors. We showed that in two ESCC patients, \(p16\) methylation occurred not only in the tumoral cells but also in the corresponding normal tissue. In the normal tissue of one of the two, \(p16\) protein was not expressed. In line with our data on \(p16\) methylation in normal tissue, Hibi et al presented one case of \(p16\) methylation in the normal tissue in addition to WBCs of peripheral blood. They suggested that individuals with \(p16\) promoter methylation of normal tissue might be prone to development of cancer. Furthermore, other studies have provided evidence of \(p16\) methylation in normal tissue. \(p16\) methylation of normal tissues, as a rare event, was also shown by Esteller et al [31]. Guan et al [32] reported the \(p16\) methylation of transitional mucosa in 2/8 colon cancer patients. We can speculate that the presence of \(p16\) methylation in normal tissue of these two studied ESCC patients may prone them to trigger tumor formation in these tissues. Although \(p16\) hypermethylation most often occurs in the late preneoplastic stages (i.e. dysplasia) [33], it seems that in a small proportion of individuals, methylation may rarely occur in the normal tissue of esophagus. Environmental factors, previously reported as influencing aberrant hypermethylation, such as exposure to carcinogens or dietary factors, [34-37], along with a possible genetic predisposition, such as DNA methyltransferase activation [38], may be responsible for the epigenetic alterations and methylation induction in the normal tissue of this small proportion. However, further large-scale studies are required to focus on this issue and validate the probable impact of lifestyle and environmental factors and possible genetic predispositions on the methylation status of normal esophageal tissue.

Regarding \(p16\) immunostaining, we did not detect hypermethylation in 7 out of 28 ESCC tumor tissues (25%) with negative \(p16\) immunostaining. This suggested that other molecular mechanisms, such as point mutation, homozygous deletion or loss of heterozygosity, may contribute to \(p16\) gene inactivation [39-41]. In 20% of ESCCs (10/50), \(p16\) protein expression was accompanied by positive \(p16\) hypermethylation. This can possibly be explained by hemi-methylation of the \(p16\) gene. It may

---

**Table 2: Correlation of \(p16/p53/MDM2\) immunoprofile in ESCC patients with \(p16\) methylation and clinicopathological features**

| Alteration | a | b | c | d | \(p\) value |
|------------|---|---|---|---|-------------|
| \(p16\) methylation | | | | | |
| Positive | 3 (33.3) | 6 (46.2) | 12 (70.6) | 10 (90.9) | 0.028 |
| Negative | 6 (66.7) | 7 (53.8) | 5 (29.4) | 1 (9.1) | |
| **Tobacco use** | | | | | |
| Positive | 2 (22.2) | 7 (58.3) | 3 (21.4) | 2 (18.2) | 0.145 |
| Negative | 7 (77.8) | 5 (41.7) | 11 (78.6) | 9 (81.8) | |
| **Histology** | | | | | |
| Well | 3 (33.3) | 7 (53.8) | 6 (50) | 9 (81.8) | 0.173 |
| Moderate | 2 (22.2) | 4 (30.8) | 5 (41.7) | 2 (18.2) | |
| Poor | 4 (44.4) | 2 (15.4) | 1 (8.3) | 0 (0.0) | |
| **Tissue** | | | | | |
| Tumor | 9 (56.2) | 13 (43.4) | 17 (80.9) | 11 (100) | 0.001 |
| Normal | 7 (43.8) | 17 (56.6) | 4 (19.1) | 0 (0.0) | |

\(^*\)\(^{p16/p53/MDM2\text{ profile}}\)
\(^{p16/p53/MDM2\text{ profile or } p16^-/p53^-/MDM2^-\text{ profile or } p16^-/p53^-/MDM2^-\text{ profile}}\)
\(^{p16^-/p53^-/MDM2^-\text{ profile or } p16^-/p53^-/MDM2^-\text{ profile or } p16^-/p53^-/MDM2^-\text{ profile}}\)
\(^{p16^-/p53^-/MDM2^-\text{ profile}}\)
also reflect the high sensitivity of the MSP method, i.e. 0.1% methylated DNA, which would indicate that tumor samples with a low proportion of methylated DNA could be considered as methylation positive by MSP even though they may withhold p16 immunoreactivity due to unmethylated tumor cells in the same sample [42].

It has been hypothesized that p53 alterations may concomitantly occur with alterations in p16INK4a in carcinogenesis [43]. As for the p53-MDM2 pathway, when the p16 methylation status was compared with the p53 and MDM2 protein expression in ESCC patients, we observed that ESCC tumors with p16 epigenetic inactivation more often harbored increased levels of p53 protein expression. To our knowledge, this is the first report indicating the association between p16 hypermethylation and p53 protein accumulation in ESCC. Lee et al detected abnormal accumulation of p53, along with p16 promoter hypermethylation in colon cancer despite the inverse correlation between them as reported by other previous studies [44]. Esteller et al showed that p53 overexpression was independent of p16 methylation status in colorectal cancer [45]. Ishii et al reported more extensive DNA methylation in neoplastic lesions of ESCC with a p53 mutation than in those with wild-type p53, when assessing the promoter hypermethylation of 14 tumor suppressor genes; however p16 hypermethylation was not independently associated with p53 mutation [46].

These observations may help us address the occurrence of combined molecular mechanisms, which are likely to play a major role in ESCC tumor progression. Since cell populations of the primary neoplasm are heterogeneous, a single marker cannot specifically and accurately predict the behavior of the tumor [47]. Abnormal p53 expression occurs concomitantly with abnormally expressed p16 or MDM2 proteins in the tumor. On the other hand, p16 hypermethylation is associated with a larger accumulation of abnormal protein expression in both p16-Rb and p53-MDM2 pathways. All these findings in addition to correlation between p16 hypermethylation and p53 abnormal accumulation, indicate a possible overlap and cross-talk between the involved pathways.

Although it has been reported that p16 hypermethylation is a predisposing epigenetic trait in the familial ESCC in Iran [21], the role of other factors such as environmental factors has not yet been ruled out. It has been reported that high-level exposure to polycyclic aromatic hydrocarbons may contribute to the high incidence of ESCC in the northeastern Iran [4]. Concomitant p16 hypermethylation and p53 overexpression may be a consequence of various environmental, dietary or lifestyle factors peculiar to this region, associated with an increased susceptibility to ESCC. However due to the lack of a precise evaluation of environmental exposures in this study, we could not strongly deduce any correlation between these factors and p16 methylation or protein expression status, as well as p53 and MDM2 overexpression.

Conclusion
In summary, we conclude that p16 gene silencing caused by hypermethylation of CpG islands may be a major mechanism in the ESCC development. It is associated with p53 protein overexpression in the ESCC patients of northeastern Iran. This is the first study indicating the association between p16 hypermethylation and p53 protein overexpression. The impact of p16 hypermethylation on accumulation of abnormally expressed proteins in the p53-MDM2 pathway, along with the observed concomitant accumulation of p53 with either MDM2 overexpression or decreased p16 expression, suggests a possible cross-talk of the involved pathways in ESCC development in northeastern Iran. Further studies of the methylation status of various cancer-related genes in a large sample size, accompanied by the assessment of exposure to the potentially harmful environmental factors, are needed to better elucidate the genetic changes occurring in ESCC carcinogenesis and tumor progression in this high risk population.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
NT carried out data collection, the molecular genetic studies, designed the questionnaire, participated in designing the study, and drafted the manuscript. FB participated in the study design and coordination. MS participated in the study design and coordination, participated in data interpretation and carried out immunohistochemistry study. HK performed the statistical analysis, interpretation of data, and participated in drafting the manuscript. RM general supervision of the research group, management of data collection and questionnaire development, participated in the study design and coordination. OM participated in epigenetic study, interpretation of data, and scientifically revised the manuscript. BM participated in the immunohistochemistry study. AA carried out epigenetic studies. MRA conceived of the study, participated in the study design and coordination, and scientifically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This study is supported by the Digestive Diseases Research Center (DDRC) of Tehran University of Medical Sciences. We gratefully acknowledge the contribution of the scientific collaborators of DDRC, Division of Human Genetics of Avicenna Research Institute of Mashhad University of Medical Sciences, and the National Institute of Genetic Engineering and Biotechnology. The results described in this paper were part of a Ph.D. student dissertation.

Author Details
1National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran, 2Digestive Disease Research Center (DDRC), Tehran University of Medical Sciences, Tehran, Iran, 3Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran and 4Department of Pathology, Omid Hospital, MUMS, Mashhad, Iran

Received: 16 November 2009 Accepted: 13 April 2010
Published: 13 April 2010
References

1. Mousavi SM, Gouy MM, Ramazani R, Deivanou R, Hajaseghi N, Sedighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009, 20(3):556-563.

2. Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh A. Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian cancer registry. Br J Cancer 1973, 28(3):197-214.

3. Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, Taghavi N, Marjani HA, Merat S, Nasseri-Moghadam S, Pourshams A, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer 2004, 90(7):1402-1406.

4. Kamangar F, Malekzadeh R, Dawsey SM, Saeid F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med 2007, 10(1):70-82.

5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003, 349(23):2241-2252.

6. Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 2001, 22(8):1119-1129.

7. El-Rifai W, Powell SM. Molecular biology of gastric cancer. Semin Radiat Oncol 2002, 12(2):18-140.

8. Arora S, Mathew R, Mathur M, Chattopadhayay TK, Ralhan R. Alterations in p53 and p53 pathways and their prognostic significance in esophageal cancer. European Journal of Cancer 2002, 38(6):832-841.

9. Tsuda H, Hashiguchi Y, Nishimura S, Kawamura N, Inoue T, Yamamoto K. Oncol Res Pract 2009, 14(1):239-247.

10. Gottlieb TM, Oren M. Relationship between HPV typing and abnormality of G1 cell cycle oscillations by the p53-Mdm2 feedback loop: a theoretical and mechanistic study. J Natl Cancer Inst 2001, 93(3):116-125.

11. Saisto S, Tissijanti S, Okka S, Ikekuchi M, Maeta M, Kaibara N. The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Ann Surg Oncol 2002, 9(5):450-456.

12. Karrass MR. Gastric cancer in association with Helicobacter pylori infection. J Surg Oncol 2005, 91(3):216-2165.

13. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ. Dren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci USA 2003, 97(21):1250-1255.

14. Gastrointestinal cancer incidence and mortality in Iran. Int J Cancer 1995, 60(1):1-7.

15. Herman JG, Baylin SB. Gene silencing in cancer: association with promoter hypermethylation. N Engl J Med 2000, 342(21):2042-2054.

16. Sato F, Metzger SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 2006, 106(3):483-493.

17. Corden-Cord C. Mutations of cell cycle regulators. Cancer Res 1995, 55(3):545-560.

18. Jang SJ. Cell cycle regulators as prognostic predictor of colorectal cancers. Korean J Gastroenterol 2004, 44(6):346-349.

19. Herman JG, Baylin SB. Gene silencing in cancer: association with promoter hypermethylation. N Engl J Med 2000, 342(21):2042-2054.

20. Sato F, Metzger SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 2006, 106(3):483-493.

21. Macaluso M, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 2003, 22(42):6472-6478.

22. Abbaszadegan MR, Razieh HR, Ghafarzadegan K, Ghavamzadeh MR, Besharat A. CpG island methylation in primary and metastatic breast tumors. World J Surg Oncol 2010, 8:53.

23. Arora S, Mathew R, Mathur M, Chattopadhayay TK, Ralhan R. Alterations in p53 and p53 pathways and their prognostic significance in esophageal cancer. European Journal of Cancer 2002, 38(6):832-841.

24. Karrass MR. Gastric cancer in association with Helicobacter pylori infection. J Surg Oncol 2005, 91(3):216-2165.

25. Mathew J, Khanna R, Mathur M, Shukla KC, Khanna R. Alterations in p53 and p53 pathways and their prognostic significance in esophageal cancer. European Journal of Cancer 2002, 38(6):832-841.

26. Zali MR, Moaven O, Asadzadegan Aghdaee H, Ghafarzadegan K, Jamii Kh, Farzadnia K, Kaviani K. Clinicopathological significance of E-cadherin, β-catenin and p53 expression in gastric adenocarcinoma. Pathol Oncol Res 2009, 14(1):159-166.

27. Xing EP, Nie Y, Song Y, Yang QY, Cai YC, Wang LD, Yang LS. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999, 5(10):2704-2713.

28. Hardie DJ, Darrton SJ, Wallis YL, Chauhan A, Hainaut P, Wild CP, Casson AG. p16 expression in Barrett’s esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 2005, 217(2):221-230.

29. Hibi K, Taguchi M, Nakayama H, Takase T, Kariy T, Ikko K, Akiyama S, Nakao A. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2003, 9(10):3135-3139.

30. Wang J, Sasco AJ, Fu C, Xue H, Guo G, Hua Z, Zhou Q, Jiang Q, Xu B. Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17(11):18-125.

31. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002, 196(1):1-7.

32. Guan RJ, Fu Y, Holt PR, Pardee AB. Association of K-ras mutations with p16 methylation in human colon cancer. Gastroenterology 1999, 116(5):1063-1071.

33. Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 2003, 83(5):635-641.

34. Cui X, Wakai T, Shirai Y, Hatakeyama K, Hirano S. p16 promoter hypermethylation as a useful serum marker for p16 methylation in human colon cancer. Gut 2000, 47(11):1713-1717.

35. Kang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr 2007, 137(7):1713-1717.

36. Karrass MR. Gastric cancer in association with Helicobacter pylori infection. J Surg Oncol 2005, 91(3):216-2165.

37. Keyes MK, Jiang H, Mason JB, Liu Z, Crott JW, Smith DE, Friso S, Choi SW. Older age and dietary folate are determinants of genomic and p16-specific DNA methylation in mouse colon. J Nutr 2007, 137(7):1713-1717.

38. McAllister A, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 2003, 22(42):6472-6478.

39. Abbaszadegan MR, Razieh HR, Ghafarzadegan K, Ghavamzadeh MR, Besharat A. CpG island methylation in primary and metastatic breast tumors. World J Surg Oncol 2010, 8:53.

40. Mathew J, Khanna R, Mathur M, Shukla KC, Khanna R. Alterations in p53 and p53 pathways and their prognostic significance in esophageal cancer. European Journal of Cancer 2002, 38(6):832-841.
45. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001, 19(2):299-304.

46. Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, Kambara T, Shirakawa Y, Naomoto Y, Ouchida M, Shimizu K, et al: Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007, 56(1):13-19

47. Esteller M: Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003, 4(6):351-358.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/138/prepub